TScan Therapeutics (TCRX) Interest Expenses (2020 - 2026)

TScan Therapeutics (TCRX) has reported Interest Expenses for 7 consecutive years, with $689000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 1.47% year-over-year to $689000.0; the TTM figure through Mar 2026 stood at $2.8 million (down 17.61% YoY), while the FY2025 annual figure was $84.0 million, up 757.07% from the prior year.
• Interest Expenses slipped to $689000.0 in Q1 2026 per TCRX's latest filing, from $702000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $1.8 million in Q4 2022 and bottomed at $201000.0 in Q3 2022.
• Historically, Interest Expenses has averaged $901066.7 across 5 years, with a median of $952000.0 in 2024.
• Annual changes were most pronounced in 2022 — Interest Expenses sank 97.87% — and 2023, when it soared 388.56%.
• TScan Therapeutics' Interest Expenses stood at $1.8 million in 2022, then declined by 16.73% to $1.5 million in 2023, then slumped by 47.66% to $784000.0 in 2024, then dropped by 10.46% to $702000.0 in 2025, then decreased by 1.85% to $689000.0 in 2026.
• Business Quant data shows TCRX's Interest Expenses at $689000.0 in Q1 2026, $702000.0 in Q4 2025, and $699000.0 in Q3 2025.